Lund, Sweden – September 1, 2023 – Fåhraeus Startup and Growth AB (FSG), a Nordic venture capital fund, today announces the first close of its fund FSG Fund II at SEK 560 million. FSG Fund II is focused on supporting life science and tech companies primarily in the Nordics and is anchored by Saminvest and prominent family office and private investors, as well as the entire FSG team.
FSG has evolved from Fårö Capital, the family office of Christer Fåhraeus established in 2000, with investments in 18 companies to its name. By early 2023, FSG Fund I had completed its investment cycle, funding 14 companies including Aqilion, Yazen and Oncorena. Maintaining its initial vision, FSG Fund II aims to invest predominantly in Nordic clinical-stage life science entities and tech companies with existing revenue streams.
“The initial close of our second fund is a testament to the compelling investment landscape in Scandinavia. We sincerely appreciate our investors’ confidence in FSG’s team to pinpoint companies that offer robust financial gains and foster sustainable operations. It’s incredibly encouraging to see many of our private investors from FSG Fund I expanding their commitment to this subsequent fund. As we progress, we are eager to take an active investment role and leverage our expertise and connections to strengthen our portfolio companies,” said Linus Wiebe, Managing Director and General Partner of FSG Fund II.
The fund will be managed by a founding team of Christer Fåhraeus, Linus Wiebe and Johanna Asklin, whose extensive operational and entrepreneurial experience, together with a strong investment track record, gives a clear advantage in identifying and building successful growth companies. Christer has founded multiple international life science and tech companies such as CellaVision AB, EQL Pharma AB and FlatFrog AB. Linus has most recently built and managed Sweden’s best-performing university spin-out portfolio, with multiple 10x exits in both tech and life science, and co-founded the silicon IP company Logipard, later acquired by ARM. Johanna has extensive experience from strategy and business development in the life science industry across Scandinavia, most recently from SAGA Diagnostics.
“By investing in innovative early-stage ventures and supporting specialized funds within tech and life science, we are not only strengthening the Swedish capital ecosystem by supporting FSG but also showcasing our commitment to fostering a robust Nordic startup community with seasoned professionals at its helm,” said Magnus Skåninger, CIO Fund Investment, Saminvest.
About Fåhraeus Startup and Growth (FSG)
Fåhraeus Startup & Growth (FSG) specialises in venture capital investments within the life science and technology sectors, primarily focusing on the Nordics. We are drawn to companies showcasing revolutionary innovations, substantial revenue growth potential and a demonstrated product-market fit. Established by seasoned life science and tech professionals, FSG Fund II combines deep industry insights with significant investment expertise. We pride ourselves on being hands-on owners, leveraging our expansive industry network to bolster the growth of our portfolio companies. At the helm of FSG Fund II are Managing Director Linus Wiebe and General Partners Christer Fåhraeus and Johanna Asklin.
FSG Fund II AB is a registered alternative investment fund under the Swedish Alternative Investment Fund Managers Act. www.fsg.vc
